Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer.
Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther. 1996 Jul-Aug; 18(4):647-57.